Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

BACKGROUND: It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. METHODS AND RESULTS: We administered 100 mg of cana...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Diabetol Metab Syndr
Main Authors: Yagi, Shusuke, Hirata, Yukina, Ise, Takayuki, Kusunose, Kenya, Yamada, Hirotsugu, Fukuda, Daiju, Salim, Hotimah Masdan, Maimaituxun, Gulinu, Nishio, Susumu, Takagawa, Yuriko, Hama, Saori, Matsuura, Tomomi, Yamaguchi, Koji, Tobiume, Takeshi, Soeki, Takeshi, Wakatsuki, Tetsuzo, Aihara, Ken-ichi, Akaike, Masashi, Shimabukuro, Michio, Sata, Masataka
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2017
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5628447/
https://ncbi.nlm.nih.gov/pubmed/29034006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13098-017-0275-4
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים